The company has tried to create new enthusiasm with with efforts to expand into hepatitis C, the viral liver disease that is looking like the next big drug market, and into other areas such as heart disease, cystic fibrosis, and pulmonary arterial hypertension.
FORBES: Gilead Tries To Revive Itself With $11 Billion Purchase Of Pharmasset